Al-Karagholi Mohammad Al-Mahdi, Ghanizada Hashmat, Nielsen Cherie Amalie Waldorff, Skandarioon Camilla, Snellman Josefin, Lopez Lopez Cristina, Hansen Jakob Møller, Ashina Messoud
Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.
Novartis Pharma AG, Basel, Switzerland.
Cephalalgia. 2020 Oct;40(11):1145-1154. doi: 10.1177/0333102420940681. Epub 2020 Aug 26.
Preclinical data implicate large conductance calcium-activated potassium (BK) channels in the pathogenesis of headache and migraine, but the exact role of these channels is still unknown. Here, we investigated whether opening of BK channels would cause headache and vascular effects in healthy volunteers.
In a randomized, double-blind, placebo-controlled, cross-over study, 21 healthy volunteers aged 18-39 years were randomly allocated to receive an intravenous infusion of 0.05 mg/min BK channel opener MaxiPost and placebo on two different days. The primary endpoints were the difference in incidence of headache and the difference in area under the curve (AUC) for headache intensity scores (0-12 hours) and for middle cerebral artery blood flow velocity (V) (0-2 hours) between MaxiPost and placebo. The secondary endpoints were the differences in area under the curve for superficial temporal artery and radial artery diameter (0-2 hours) between MaxiPost and placebo.
Twenty participants completed the study. Eighteen participants (90%) developed headache after MaxiPost compared with six (30%) after placebo ( = 0.0005); the difference of incidence is 60% (95% confidence interval 36-84%). The area under the curve for headache intensity (AUC, = 0.0003), for mean V (AUC, = 0.0001), for superficial temporal artery diameter (AUC, = 0.003), and for radial artery diameter (AUC, = 0.03) were significantly larger after MaxiPost compared to placebo.
MaxiPost caused headache and dilation in extra- and intracerebral arteries. Our findings suggest a possible role of BK channels in headache pathophysiology in humans. ClinicalTrials.gov, ID: NCT03887325.
临床前数据表明,大电导钙激活钾(BK)通道与头痛和偏头痛的发病机制有关,但这些通道的确切作用仍不清楚。在此,我们研究了BK通道开放是否会在健康志愿者中引起头痛和血管效应。
在一项随机、双盲、安慰剂对照、交叉研究中,21名年龄在18至39岁之间的健康志愿者被随机分配在两个不同的日子接受静脉输注0.05mg/min的BK通道开放剂MaxiPost和安慰剂。主要终点是MaxiPost与安慰剂之间头痛发生率的差异以及头痛强度评分(0至12小时)和大脑中动脉血流速度(V)(0至2小时)的曲线下面积(AUC)差异。次要终点是MaxiPost与安慰剂之间颞浅动脉和桡动脉直径的曲线下面积(0至2小时)差异。
20名参与者完成了研究。与安慰剂组6名(30%)相比,18名参与者(90%)在接受MaxiPost后出现头痛(P = 0.0005);发生率差异为60%(95%置信区间36 - 84%)。与安慰剂相比,MaxiPost后的头痛强度曲线下面积(AUC,P = 0.0003)、平均V曲线下面积(AUC,P = 0.0001)、颞浅动脉直径曲线下面积(AUC,P = 0.003)和桡动脉直径曲线下面积(AUC,P = 0.03)均显著更大。
MaxiPost引起了颅外和颅内动脉的头痛和扩张。我们的研究结果表明BK通道在人类头痛病理生理学中可能发挥作用。ClinicalTrials.gov,标识符:NCT03887325。